Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma

Biomarkers in Medicine

Volumn 9, Issue 1, 2015, Pages 13-23

  Rubinger, Daniel A ^a   Hollmann, Sarah S ^a   Serdetchnaia, Viktoria ^a   Ernst, D Scott ^b   Parker, Jayson L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Biomarker; clinical trial risk; drug approval; drug development; metastatic melanoma

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; DABRAFENIB; IPILIMUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

B RAF GENE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; METASTATIC MELANOMA; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; VALIDITY; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; MELANOMA; NEOPLASM METASTASIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84921698023     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.80     Document Type: Review

References (43)

1. American Cancer Society. Cancer Facts and Figures 2014. www.cancer.org
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
3. Karim-Kos HE, De Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur. J. Cancer 44(10), 1345-1389 (2008).
4. Bataille V, De Vries E. Melanoma-part 1: epidemiology, risk factors, and prevention. BMJ 337, a2249 (2008).
5. Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol. Online J. 15(11), 1 (2009).
6. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur. J. Cancer 47(14), 2150-2157 (2011).
7. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191-200 (2012).
8. Allison M. Reinventing clinical trials. Nat. Biotechnol. 30(1), 41-49 (2012).
9. US FDA. E16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. www.fda.gov
10. Jenkins M, Flynn A, Smart T et al. A statistician's perspective on biomarkers in drug development. Pharm. Stat. 10(6), 494-507 (2011).
11. Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 22(2), 114-122 (2012).
12. Reid GGJ, Bin Yameer TA, Parker JL. Impact of biomarkers on clinical trial risk. Pharmacogenomics 14(13), 1645-1658 (2013).
13. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13(1-2), 30-37 (2008).
14. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87(3), 272-277 (2010).
15. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10(5), 328-329 (2011).
16. Hayashi K, Masuda S, Kimura H. Impact of biomarker usage on oncology drug development. J. Clin. Pharm. Ther. 38(1), 62-67 (2013).
17. Dimasi JA, Grabowski HG. Economics of new oncology drug development. J. Clin. Oncol. 25(2), 209-216 (2007).
18. Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res. Treat. 136(1), 179-185 (2012).
19. Falconi A, Lopes G, Parker JL. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J. Thorac. Oncol. 9(2), 163-169 (2014).
20. Jayasundara KS, Keystone EC, Parker JL. Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis. J. Rheumatol. 39(11), 2066-2070 (2012).
21. Osborne BJW, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: the effect of drug class. J. Pharm. Health Serv. Res. 2(4), 211-216 (2011).
22. Parker JL, Clare Kohler J. The success rate of new drug development in clinical trials: Crohn's disease. J. Pharm. Pharm. Sci. 13(2), 191-197 (2010).
23. Parker JL, Zhang ZY, Buckstein R. Clinical trial risk in non-Hodgkin's lymphoma: endpoint and target selection. J. Pharm. Pharm. Sci. 14(2), 227-235 (2011).
24. Tenuta A, Klotz L, Parker JL. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise. BJU Int. 113(5b), E82-E89 (2014).
25. NIH clinical trials database. http://clinicaltrials.gov
26. Archive-It. www.archive-it.org.
27. Factiva. http://global.factiva.com
28. Proquest 5000. http://search.proquest.com
29. US FDA. Frequently asked questions about therapeutic biological products. www.fda.gov
30. US FDA. Guidance for industry (draft): clinical considerations for therapeutic cancer vaccines. www.fda.gov
31. US FDA. Guidance for industry: qualification process for drug development tools. www.fda.gov
32. Chau CH, Rixe O, Mcleod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 14(19), 5967-5976 (2008).
33. Ballantyne AD, Garnock-Jones KP. Dabrafenib. First global approval. Drugs 73(12), 1367-1376 (2013).
34. Wright CJ, McCormack PL. Trametinib. First global approval. Drugs 73(11), 1245-1254 (2013).
35. US FDA. News release: FDA approves new treatment for a type of late-stage skin cancer. www.fda.gov
36. US FDA. News release: FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. www.fda.gov
37. US FDA. Table of pharmacogenomic biomarkers in drug labels. www.fda.gov
38. US FDA. Draft guidance for industry and Food and Drug Administration staff: in vitro companion diagnostic devices. www.fda.gov
39. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin. Proc. 81(4), 500-507 (2006).
40. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 445(7130), 851-857 (2007).
41. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239(1), 27-44 (2011).
42. Melanoma Vaccine-AVAX Technologies: DNP-VACC, M-Vax. BioDrugs 17(1), 69-72 (2003).
43. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a Phase III trial (MDX010-20). Ann. Oncol. 24(10), 2694-2698 (2013).